On the public citation graph
Cost-effectiveness of activated protein C in real-life clinical practice
0 signed · 67 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.1995.03530080055041openalex-snapshot
The Prevalence of Nosocomial Infection in Intensive Care Units in Europe
inferredcites →https://doi.org/10.1001/jama.1996.03540100046027openalex-snapshot
The Logistic Organ Dysfunction System
inferredcites →https://doi.org/10.1001/jama.1997.03540370048035openalex-snapshot
Magnitude and Duration of the Effect of Sepsis on Survival
inferredcites →https://doi.org/10.1001/jama.270.24.2957openalex-snapshot
A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study
inferredcites →https://doi.org/10.1001/jama.274.8.639openalex-snapshot
The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee
inferredcites →https://doi.org/10.1001/jama.276.10.802openalex-snapshot
The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group
inferredcites →https://doi.org/10.1001/jama.288.7.862openalex-snapshot
Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock
inferredcites →https://doi.org/10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-bopenalex-snapshot
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
inferredcites →https://doi.org/10.1002/hec.4730030505openalex-snapshot
Costs, effects and C/E‐ratios alongside a clinical trial
inferredcites →https://doi.org/10.1002/hec.584openalex-snapshot
The death of cost‐minimization analysis?
inferredcites →https://doi.org/10.1002/hec.678openalex-snapshot
Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis
inferredcites →https://doi.org/10.1007/978-1-4899-4541-9openalex-snapshot
An Introduction to the Bootstrap
inferredcites →https://doi.org/10.1007/978-3-662-13450-4_18openalex-snapshot
The Logistic Organ Dysfunction System
inferredcites →https://doi.org/10.1007/bf03262331openalex-snapshot
An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures
inferredcites →https://doi.org/10.1007/s00134-002-1345-zopenalex-snapshot
Quality of life after intensive care – evaluation with EQ-5D questionnaire
inferredcites →https://doi.org/10.1007/s00134-003-1731-1openalex-snapshot
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
inferredcites →https://doi.org/10.1007/s00134-003-2121-4openalex-snapshot
EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units
inferredcites →https://doi.org/10.1007/s00134-006-0086-9openalex-snapshot
When a single pivotal trial should not be enough–the case of drotrecogin-alfa (activated)
inferredcites →https://doi.org/10.1007/s001340000760openalex-snapshot
A cost-effectiveness analysis of stays in intensive care units
inferredcites →https://doi.org/10.1007/s001340050336openalex-snapshot
Quality of life 6 months after intensive care: results of a prospective multicenter study using a generic health status scale and a satisfaction scale
inferredcites →https://doi.org/10.1016/j.evalprogplan.2005.01.004openalex-snapshot
Estimating causal effects of public health education campaigns using propensity score methodology
inferredcites →https://doi.org/10.1016/j.jcrc.2003.08.009openalex-snapshot
Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis
inferredcites →https://doi.org/10.1016/j.jcrc.2003.10.005openalex-snapshot
Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany
inferredcites →https://doi.org/10.1016/s0895-4356(00)00321-8openalex-snapshot
Validating recommendations for coronary angiography following acute myocardial infarction in the elderly
inferredcites →https://doi.org/10.1017/s0266462306050896openalex-snapshot
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure
inferredcites →https://doi.org/10.1056/nejm200103083441001openalex-snapshot
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
inferredcites →https://doi.org/10.1056/nejmsa020969openalex-snapshot
An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis
inferredcites →https://doi.org/10.1097/00003246-200107000-00002openalex-snapshot
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
inferredcites →https://doi.org/10.1097/00003246-200107001-00035openalex-snapshot
Epidemiology of sepsis: An update
inferredcites →https://doi.org/10.1097/00003246-200301000-00001openalex-snapshot
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*
inferredcites →https://doi.org/10.1097/00003246-200301000-00002openalex-snapshot
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
inferredcites →https://doi.org/10.1097/01.blo.0000079325.41006.95openalex-snapshot
Methodologic Issues in Observational Studies
inferredcites →https://doi.org/10.1097/01.ccm.0000181729.46010.83openalex-snapshot
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*
inferredcites →https://doi.org/10.1097/01.ccm.0000198329.85851.8eopenalex-snapshot
Prescribing indications based on successful clinical trials in sepsis: A difficult exercise
inferredcites →https://doi.org/10.1111/j.1365-2044.2004.04068.xopenalex-snapshot
Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom*
inferredcites →https://doi.org/10.1186/cc3778openalex-snapshot
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
inferredcites →https://doi.org/10.1186/cc4909openalex-snapshot
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
inferredcites →https://doi.org/10.1201/9780429246593openalex-snapshot
An Introduction to the Bootstrap
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1007/978-0-387-92278-2_13openalex-snapshot
Economic and Social Burden of Severe Sepsis
inferred← citeshttps://doi.org/10.1007/978-2-8178-0287-9_8openalex-snapshot
Soins des patients âgés en réanimation
inferred← citeshttps://doi.org/10.1007/978-3-540-92276-6_13openalex-snapshot
Economic and Social Burden of Severe Sepsis
inferred← citeshttps://doi.org/10.1007/s00134-010-1991-5openalex-snapshot
Propensity scores in intensive care and anaesthesiology literature: a systematic review
inferred← citeshttps://doi.org/10.1007/s10877-024-01257-9openalex-snapshot
Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2014.02.018openalex-snapshot
Observational studies using propensity score analysis underestimated the effect sizes in critical care medicine
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2014.11.024openalex-snapshot
Combining apples and oranges obtains common features of fruit
inferred← citeshttps://doi.org/10.1016/j.jcrc.2014.05.023openalex-snapshot
Do the observational studies using propensity score analysis agree with randomized controlled trials in the area of sepsis?
inferred← citeshttps://doi.org/10.1016/j.jinf.2016.11.006openalex-snapshot
Hospital-related cost of sepsis: A systematic review
inferred← citeshttps://doi.org/10.1016/j.pharma.2013.08.009openalex-snapshot
Contrats de risk-sharing : choix des schémas d’étude et des critères de jugement
inferred← citeshttps://doi.org/10.1016/j.pharma.2021.06.004openalex-snapshot
Évaluer autrement les parcours de soins coordonnés article 51 LFSS 2018 : une innovation, les protocoles réalistes
inferred← citeshttps://doi.org/10.1016/s1473-3099(12)70157-3openalex-snapshot
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression
inferred← citeshttps://doi.org/10.1097/aco.0b013e328323f9a8openalex-snapshot
Economics and outcome in the intensive care unit
inferred← citeshttps://doi.org/10.1097/cce.0000000000001288openalex-snapshot
Health Economic Evaluations in Intensive Care: An Updated Systematic Review
inferred← citeshttps://doi.org/10.1097/ccm.0000000000003768openalex-snapshot
Cost-Effectiveness Studies in the ICU: A Systematic Review*
inferred← citeshttps://doi.org/10.1097/ccm.0000000000004851openalex-snapshot
Health-Related Quality-of-Life and Cost Utility Analyses in Critical Care: A Systematic Review*
inferred← citeshttps://doi.org/10.1111/j.1524-4733.2008.00319.xopenalex-snapshot
Drotrecogin Alfa's Impact on Intensive Care Workload in Real Life Practice: A Propensity Score Approach
inferred← citeshttps://doi.org/10.1136/bmjopen-2014-006524openalex-snapshot
The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approach
inferred← citeshttps://doi.org/10.1186/cc10468openalex-snapshot
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
inferred← citeshttps://doi.org/10.1186/cc6090openalex-snapshot
Activated protein C: cost-effective or costly?
inferred← citeshttps://doi.org/10.1186/cc6879openalex-snapshot
Drotrecogin alfa (activated): real-life use and outcomes for the UK
inferred← citeshttps://doi.org/10.1186/cc6951openalex-snapshot
Year in review 2007: Critical Care – intensive care unit management
inferred← citeshttps://doi.org/10.1186/cc7936openalex-snapshot
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
inferred← citeshttps://doi.org/10.1186/s40560-019-0412-2openalex-snapshot
Health economic evaluations of sepsis interventions in critically ill adult patients: a systematic review
inferred← citeshttps://doi.org/10.3390/healthcare13212783openalex-snapshot
Cost-Effectiveness in Critical Care: A Systematic Review of Empirical Evaluations
inferred← citeshttps://doi.org/10.3917/rfas.144.0156openalex-snapshot
Paiement à la performance et fixation conditionnelle du prix du médicament
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.